Clinical Outcomes for Patients with Acute Myeloid Leukemia harboring IDH1 mutation after Intensive Chemotherapy

Abstract

Acute myeloid leukemia (AML) is heterogeneous myeloid disorder with multifactorial pathogenic mechanisms and a broad range of prognosis. AML is characterized by clonal proliferation of poorly differentiated cells of the myeloid lineage. The pathogenesis involves recurrent genomic alterations, including somatic gene mutations and/or chromosomal abnormalities that can define biologically distinct clinical subtypes. Comprehensive genomic profiling at the time of diagnosis can inform disease classification, risk stratification and prognosis and ultimately allow for more selective therapeutic interventions. Alterations to cellular metabolism, as well as somatic mutations of genes essential to epigenetic regulation, are implicated in the pathogenesis of several human malignancies.